SCHEMBL786245

SCHEMBL786245

NC(=O)c1cc(Br)ccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.68
ALDH1A1 P00352 2/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
DGAT1 O75907 1/20 0.46
ADORA3 P0DMS8 1/20 0.45
TSHR P16473 1/20 0.45
MC4R P32245 1/20 0.45
ADRA1A P35348 1/20 0.45
MC3R P41968 1/20 0.45
PARP1 P09874 1/20 0.44
CDC7 O00311 3/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
PLAT P00750 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
GRM5 P41594 1/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30141515 1.00 KDM4E (0.68) KDM4EALDH1A1SMN1; SMN2DGAT1ADORA3
SCHEMBL31009108 0.81 ALDH1A1 (0.59) KDM4EALDH1A1SMN1; SMN2DGAT1ADORA3
SCHEMBL100727 0.81 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2GRM5L3MBTL1
SCHEMBL29478760 0.79 ALDH1A1 (0.68) KDM4EALDH1A1SMN1; SMN2TSHRGRM5
SCHEMBL7436876 0.79 ALDH1A1 (0.68) KDM4EALDH1A1SMN1; SMN2PLGPLAU
Hydrochloric Acid SCHEMBL11679600 0.79 KDM4E (0.96) KDM4EALDH1A1SMN1; SMN2GRM5L3MBTL1
SCHEMBL31514843 0.79 ALDH1A1 (0.68) KDM4EALDH1A1SMN1; SMN2PLGPLAU
Hydrochloric Acid SCHEMBL4524886 0.79 SMN1; SMN2 (0.57) KDM4EALDH1A1SMN1; SMN2DGAT1PARP1
SCHEMBL12851523 0.79 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2DGAT1PLG
SCHEMBL5700497 0.79 ALDH1A1 (0.68) KDM4EALDH1A1SMN1; SMN2TSHRGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108752270-A A kind of 4- bromo-2-pyridyl amides compounds of the ether structure containing hexichol 湖南博隽生物医药有限公司 2018-11-06 CN claimed
CN-105153023-B The synthetic method of 2 amino, 4 bromopyridine 成都同创源医药科技有限公司 2018-04-13 CN claimed
CN-105153023-A Synthetic method of 2-amino-4-bromopyridine CHENGDU TONGCHUANGYUAN PHARMACEUTICAL CO LTD 2015-12-16 CN claimed
CN-101704781-B Preparation method of amino pyridine bromide compound UNIV JIANGSU POLYTECHNIC 2012-05-30 CN claimed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US claimed
CN-101704781-A Preparation method of amino pyridine bromide compound UNIV JIANGSU POLYTECHNIC 2010-05-12 CN claimed
US-20260034125-A1 N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-02-05 US disclosed
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 US disclosed
US-20250339425-A1 Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands UNIV NORTHEASTERN (US) 2025-11-06 US disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) 2025-09-04 US disclosed
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
WO-2008118455-A1 δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS AMGEN INC. (US) 2008-10-02 WO disclosed
EP-1289984-A4 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF DONG A PHARM CO LTD (KR) 2004-11-24 EP disclosed
US-6689779-B2 PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY DONG A PHARM. CO., LTD. (KR) 2004-02-10 US disclosed
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof DONG A PHARM. CO., LTD. (KR) 2003-09-04 US disclosed
CN-1433413-A Oxazolidinone derivatives and process for their preparation DONG A PHARM CO LTD (KR) 2003-07-30 CN disclosed
EP-1289984-A1 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF Dong A Pharmaceutical Co. Ltd. (KR) 2003-03-12 EP disclosed
WO-2001094342-A1 NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF DONG A PHARM. CO., LTD. (KR) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339425-A1 Alpha9 and Alpha7 Nicotinic Acetylcholine Receptor Ligands CHRNA9, CHRNA7, CHRNA1 KDM4E 3415/4885ALDH1A1 1214/4885SMN1; SMN2 2910/4885
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof OXA1L, ODC1, PDCD4 KDM4E 1158/4885ALDH1A1 939/4885SMN1; SMN2 3402/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP KDM4E 4163/4885ALDH1A1 4626/4885SMN1; SMN2 3657/4885
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 KDM4E 140/4885ALDH1A1 1202/4885SMN1; SMN2 3446/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDM4E 4591/4885ALDH1A1 3927/4885SMN1; SMN2 3096/4885
US-20260034125-A1 N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS CCR6, CCR1, CCR4 KDM4E 3365/4885ALDH1A1 1966/4885SMN1; SMN2 2462/4885
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS CCR6, CCR4, CCR1 KDM4E 1467/4885ALDH1A1 3366/4885SMN1; SMN2 2965/4885
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS PACSIN2, CSNK1A1, CSNK1G3 KDM4E 1708/4885ALDH1A1 4340/4885SMN1; SMN2 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.